Ana Antonia Dias Maile, Theo O J Gruendler, Adrian G Fischer, Hannah Kurtenbach, Luca F Kaiser, Monja I Froböse, Gerhard Jocham
{"title":"多巴胺对奖励导向决策的双向调节。","authors":"Ana Antonia Dias Maile, Theo O J Gruendler, Adrian G Fischer, Hannah Kurtenbach, Luca F Kaiser, Monja I Froböse, Gerhard Jocham","doi":"10.1007/s00213-025-06816-9","DOIUrl":null,"url":null,"abstract":"<p><strong>Rationale: </strong>The neuromodulator dopamine is known to play a key role in reward-guided decision making, where choice options are often characterized by multiple attributes. Different decision strategies can be used to merge these choice attributes with personal preferences (e.g., risk preferences) and integrate them into a single subjective value. While the influence of dopamine on risk preferences has been investigated, it is unknown whether dopamine is also involved in arbitrating between decision strategies.</p><p><strong>Objective: </strong>In the present study, we investigate the effects of pharmacological dopamine manipulations on arbitrating between different decision strategies in a healthy sample.</p><p><strong>Methods: </strong>31 healthy male participants performed a reward-guided decision-making task under the influence of the dopamine D<sub>2</sub>/D<sub>3</sub>-receptor antagonist amisulpride (400 mg), the dopamine precursor L-DOPA (100 mg L-DOPA + 25 mg cardidopa), or placebo in a double-blind within-subject design. The effect of dopamine on reward-guided decisions and decision strategies was analyzed using hierarchical implementations of regressions and Bayesian models.</p><p><strong>Results: </strong>Notably, we observed that the dopaminergic interventions shifted the (overall) weighting of option attributes without changing how option attributes are integrated into a subjective value (decision strategy). These effects were bidirectional: Amisulpride reduced whereas L-DOPA increased the degree to which choices were influenced by both reward magnitude and reward probability. These effects occurred in the absence of changes in statistically optimal behavior.</p><p><strong>Conclusion: </strong>Together, our data provide evidence for a role of dopamine in controlling the influence of value parameters on choice irrespective of decision strategies.</p>","PeriodicalId":20783,"journal":{"name":"Psychopharmacology","volume":" ","pages":""},"PeriodicalIF":3.5000,"publicationDate":"2025-05-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Bidirectional modulation of reward-guided decision making by dopamine.\",\"authors\":\"Ana Antonia Dias Maile, Theo O J Gruendler, Adrian G Fischer, Hannah Kurtenbach, Luca F Kaiser, Monja I Froböse, Gerhard Jocham\",\"doi\":\"10.1007/s00213-025-06816-9\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Rationale: </strong>The neuromodulator dopamine is known to play a key role in reward-guided decision making, where choice options are often characterized by multiple attributes. Different decision strategies can be used to merge these choice attributes with personal preferences (e.g., risk preferences) and integrate them into a single subjective value. While the influence of dopamine on risk preferences has been investigated, it is unknown whether dopamine is also involved in arbitrating between decision strategies.</p><p><strong>Objective: </strong>In the present study, we investigate the effects of pharmacological dopamine manipulations on arbitrating between different decision strategies in a healthy sample.</p><p><strong>Methods: </strong>31 healthy male participants performed a reward-guided decision-making task under the influence of the dopamine D<sub>2</sub>/D<sub>3</sub>-receptor antagonist amisulpride (400 mg), the dopamine precursor L-DOPA (100 mg L-DOPA + 25 mg cardidopa), or placebo in a double-blind within-subject design. The effect of dopamine on reward-guided decisions and decision strategies was analyzed using hierarchical implementations of regressions and Bayesian models.</p><p><strong>Results: </strong>Notably, we observed that the dopaminergic interventions shifted the (overall) weighting of option attributes without changing how option attributes are integrated into a subjective value (decision strategy). These effects were bidirectional: Amisulpride reduced whereas L-DOPA increased the degree to which choices were influenced by both reward magnitude and reward probability. These effects occurred in the absence of changes in statistically optimal behavior.</p><p><strong>Conclusion: </strong>Together, our data provide evidence for a role of dopamine in controlling the influence of value parameters on choice irrespective of decision strategies.</p>\",\"PeriodicalId\":20783,\"journal\":{\"name\":\"Psychopharmacology\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":3.5000,\"publicationDate\":\"2025-05-29\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Psychopharmacology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1007/s00213-025-06816-9\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"NEUROSCIENCES\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Psychopharmacology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s00213-025-06816-9","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"NEUROSCIENCES","Score":null,"Total":0}
Bidirectional modulation of reward-guided decision making by dopamine.
Rationale: The neuromodulator dopamine is known to play a key role in reward-guided decision making, where choice options are often characterized by multiple attributes. Different decision strategies can be used to merge these choice attributes with personal preferences (e.g., risk preferences) and integrate them into a single subjective value. While the influence of dopamine on risk preferences has been investigated, it is unknown whether dopamine is also involved in arbitrating between decision strategies.
Objective: In the present study, we investigate the effects of pharmacological dopamine manipulations on arbitrating between different decision strategies in a healthy sample.
Methods: 31 healthy male participants performed a reward-guided decision-making task under the influence of the dopamine D2/D3-receptor antagonist amisulpride (400 mg), the dopamine precursor L-DOPA (100 mg L-DOPA + 25 mg cardidopa), or placebo in a double-blind within-subject design. The effect of dopamine on reward-guided decisions and decision strategies was analyzed using hierarchical implementations of regressions and Bayesian models.
Results: Notably, we observed that the dopaminergic interventions shifted the (overall) weighting of option attributes without changing how option attributes are integrated into a subjective value (decision strategy). These effects were bidirectional: Amisulpride reduced whereas L-DOPA increased the degree to which choices were influenced by both reward magnitude and reward probability. These effects occurred in the absence of changes in statistically optimal behavior.
Conclusion: Together, our data provide evidence for a role of dopamine in controlling the influence of value parameters on choice irrespective of decision strategies.
期刊介绍：
Official Journal of the European Behavioural Pharmacology Society (EBPS)
Psychopharmacology is an international journal that covers the broad topic of elucidating mechanisms by which drugs affect behavior. The scope of the journal encompasses the following fields:
Human Psychopharmacology: Experimental
This section includes manuscripts describing the effects of drugs on mood, behavior, cognition and physiology in humans. The journal encourages submissions that involve brain imaging, genetics, neuroendocrinology, and developmental topics. Usually manuscripts in this section describe studies conducted under controlled conditions, but occasionally descriptive or observational studies are also considered.
Human Psychopharmacology: Clinical and Translational
This section comprises studies addressing the broad intersection of drugs and psychiatric illness. This includes not only clinical trials and studies of drug usage and metabolism, drug surveillance, and pharmacoepidemiology, but also work utilizing the entire range of clinically relevant methodologies, including neuroimaging, pharmacogenetics, cognitive science, biomarkers, and others. Work directed toward the translation of preclinical to clinical knowledge is especially encouraged. The key feature of submissions to this section is that they involve a focus on clinical aspects.
Preclinical psychopharmacology: Behavioral and Neural
This section considers reports on the effects of compounds with defined chemical structures on any aspect of behavior, in particular when correlated with neurochemical effects, in species other than humans. Manuscripts containing neuroscientific techniques in combination with behavior are welcome. We encourage reports of studies that provide insight into the mechanisms of drug action, at the behavioral and molecular levels.
Preclinical Psychopharmacology: Translational
This section considers manuscripts that enhance the confidence in a central mechanism that could be of therapeutic value for psychiatric or neurological patients, using disease-relevant preclinical models and tests, or that report on preclinical manipulations and challenges that have the potential to be translated to the clinic. Studies aiming at the refinement of preclinical models based upon clinical findings (back-translation) will also be considered. The journal particularly encourages submissions that integrate measures of target tissue exposure, activity on the molecular target and/or modulation of the targeted biochemical pathways.
Preclinical Psychopharmacology: Molecular, Genetic and Epigenetic
This section focuses on the molecular and cellular actions of neuropharmacological agents / drugs, and the identification / validation of drug targets affecting the CNS in health and disease. We particularly encourage studies that provide insight into the mechanisms of drug action at the molecular level. Manuscripts containing evidence for genetic or epigenetic effects on neurochemistry or behavior are welcome.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
